Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors
Abstract Iruplinalkib (WX‐0593), a selective oral ALK/ROS1 tyrosine kinase inhibitor, was approved in China as first‐line therapy for ALK‐positive non‐small‐cell lung cancer (NSCLC) and for the treatment of locally advanced or metastatic ALK‐positive NSCLC that has progressed following crizotinib th...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.70099 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|